Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford researcher have found a promising future treatment for heart disease, going back to a drug first developed in 1950.

Hydroxychloroquine (HCQ) was created to combat malaria, and was later found to be useful in the treatment of Lupus and rheumatoid arthritis. Now, a team at Oxford University's Departments of Pharmacology and of Physiology, Anatomy and Genetics has found that the drug can also reduce heart rate. Their report*, to be published in journal Heart Rhythm, says that the treatment could benefit people with heart failure.

Dr Rebecca Burton, who led the research, said: "The starting point was a chance observation. A patient being treated for Lupus also had a high heart rate. When the patient started Hydroxychloroquine for the Lupus, their heart rate reduced. We started to think about how the drug might be acting in the heart and began extensive pre-clinical studies in collaboration with [Oxford University heart specialists] Professor Derek Terrar and Professor David Paterson."

Researchers found that the drug acts on an area of the heart called the sino-atrial node. This group of cells keeps the heart beating by producing a rhythmic electrical signal that is transmitted to the rest of the heart muscle. Within the node HCQ targets a particular protein to restrict an electrical signal known as the 'funny current' that is especially important in setting the heart rate.

The effects of HCQ on the heart were studied in the late 1950s but initial findings were not followed up. There were also reports of lowered heart rate as a side-effect in patients treated for other conditions. But the potential of HCQ as a heart treatment had not been pursued fully until the Oxford team began their research.

Dr Burton said: "There is a big drive to find new purposes for existing drugs because it can save years of expensive development and testing. Established drugs have gone through a lot of the regulatory process already. However, the number of drugs on the market and the number of possible conditions are so huge that it takes a fortuitous observation to connect something which might be viewed as an annoying side-effect to something which could have a clinical benefit."

HCQ has a well-established safety profile. Side-effects are limited and well understood, and it is possible to use it for children and pregnant women under specialist care. The Oxford team’s initial research concentrated on understanding the effects of HCQ and the way in which it worked on the heart as well as safety. HCQ has the potential to be used for heart failure, high blood pressure and angina among other conditions.

The team have patented their results and are now working with the University of Oxford’s company Isis Innovation to partner with industry in order to complete clinical trials.

Dr Rebecca Capel, the paper’s first author, said: "This treatment has the potential to improve the quality of life for patients who are not responding well to standard heart treatments. There are some very exciting possibilities but we need to go through the full process of clinical trials to really understand its full potential."

Professor Jeremy Pearson, Associate Medical Director at the British Heart Foundation, which funds both Dr Caplan and Dr Burton and which part funded the study, said: "This study is an elegant example of how a chance clinical observation, carefully followed up, can provide evidence in favour of an unexpected new use for an old drug."

Source: University of Oxford website

 

* Rebecca Anne Capel DPhil, Neil Herring DPhil, MRCP, Manish Kalla BSc (Hons), MBBS, MRCP, Arash Yavari BSc (Hons), MBBS, MRCP, DPhil, Gary R. Mirams Ph.D., Gillian Douglas PhD, Gil Bub PhD, Keith Channon MD, FRCP, FMedSci, David J. Paterson DPhil, DSc, Derek Terrar PhD, Rebecca-Ann B. Burton MSc, MBA, DPhil, Hydroxychloroquine reduces heart rate by modulating the hyperpolarisation-activated current ‘If’: Novel electrophysiological insights and therapeutic potential, Heart Rhythm, http://dx.doi.org/10.1016/j.hrthm.2015.05.027

Similar stories

New computational technique reveals changes to lung function post COVID-19 infection

A collaborative DPAG-led study studied patients at six and twelve months after COVID-19 infection, finding that prior COVID-19 infection was associated with more uneven inflation of the lungs during normal breathing. There was also an association between hospitalisation with COVID-19 and smaller lung volumes, and admission to the intensive care unit (ICU) was associated with an enlarged respiratory dead space.

BHF funded DPAG projects to receive share of £2 million raised by the London Marathon

The British Heart Foundation were charity of the year for the 2022 TCS London Marathon. Around 800 BHF London Marathon runners, including former De Val lab researcher Dr Alice Preston, have raised nearly £2 million, and rising, for BHF-funded science that could lead to improved new treatments for heart failure. Research led by Associate Professor Sarah De Val and Dr Joaquim Vieira are two of eight projects to receive funding from these proceeds.

New evidence for how our brains handle surprise

A new study from the Bruno Group is challenging our perceptions of how the different regions of the cerebral cortex function. A group of ‘quiet’ cells in the somatosensory cortex that rarely respond to touch have been found to react mainly to surprising circumstances. The results suggest their function is not necessarily driven by touch, but may indicate an important and previously unidentified role across all the major cortices.

Professor Dame Sue Black to deliver 2022 Christmas Lectures

In the 2022 Christmas Lectures from the Royal Institution, DPAG's Visiting Professor of Forensic Anatomy Dame Sue Black will share secrets of forensic science.

Kaitlyn Dennis to receive the William C Stanley Early Investigator Award

Congratulations are in order for DPhil student Kaitlyn Dennis, who has been awarded the William C Stanley Early Investigator Award. The award highlights the scientific accomplishments of promising young researchers and is a major focus of the Annual Meeting of the Society for Heart and Vascular Metabolism.